To the Editor
=============

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a hyper-inflammatory clinical syndrome mainly caused by severe infections, autoimmune inflammatory disorders and malignancies, especially lymphoma \[[@B1]-[@B3]\]. Up to date, very few data from the literature are available regarding the role of ^18^F-FDG PET/CT in sHLH. In this study, 18 of 50 patients with sHLH who were admitted into our hospital between May 2007 and December 2010 underwent the examination (Table [1](#T1){ref-type="table"}). The male-to-female ratio was 1:1, and the median age was 35 years (15-73). The diagnosis of HLH was made according to HLH-2004 diagnostic guidelines \[[@B4],[@B5]\], and the underlying diseases were confirmed by a series of pathogenesis examinations including pathology, immunology, bacterial culture and virus detection et al. The maximum standardized uptake values (SUV~max~) used to measure the level of FDG uptake were determined in all lesions \[[@B6]\]. All of the 18 patients had at least 3 organs involved, with increased FDG uptake at different level, including 18 cases showing splenomegaly, 16 cases serous effusions, 16 cases lymphadenopathy, 13 cases bone lesions, 12 cases pneumonia, 8 cases hepatomegaly, 5 cases brain parenchymal or cerebroventricular lesions, 5 cases cholecystitis, 4 cases myocardium lesions, and 2 cases kidney calculi. There were also other organs involved, such as larynx, muscles and adnexauteri. Fifteen patients (15/18) had definite underlying diseases, and were divided into three groups.,including Infection Associated HLH (IAHLH, including EBV-HLH, n = 8), Rheumatosis Associated HLH (RAHLH, n = 2), and Malignancy Associated HLH (MAHLH, n = 5). The SUV~max~ of patients in MAHLH group was significantly higher than those of patients with IAHLH (Mean 12.0 *vs.* 6.8, *P* = 0.015), and RAHLH (Mean 12.0 *vs.* 2.7, *P* = 0.045). Furthermore, the SUV~max~ of patients with IAHLH was significantly higher than that of patients with RAHLH (Mean 6.8 *vs.* 2.7, *P* = 0.043). However, no significant difference in survival time was found between the three different sHLH subtype according to Kaplan-Meier analysis (*P* \>0.05). In conclusion, ^18^F-FDG PET/CT may play important role in differential diagnosis of sHLH, with high SUV pointing toward underlying malignancy.

###### 

Characteristics of 18 sHLH patients

  **No.**   **Age/ Sex**   **Underlying disease**   **Therapy**                                                                   **Outcome**                                          **Survival (month)**   **Organs**   **SUV**~**max**~
  --------- -------------- ------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------- ---------------------- ------------ ------------------
  1         35/M           Lymphoma (NK / T)        IVIG/HLH-2004 regimen(1 cycle) → High-dose methylprednisolone pulse therapy   Died of intracranial hemorrhage                      1.7                    6            12.3
  2         35/F           Lymphoma (NK / T)        The Hyper-CVAD regimen (1 cycle)                                              Died of intracranial hemorrhage                      1.2                    6            15.7
  3         18/M           Lymphoma (NK / T)        The CHOP regimen(1 cycle)                                                     Died of acute hemorrhage of gastrointestinal tract   0.3                    7            14.6
  4         56/M           Lymphoma                 Hydrocortisone 100mg×5d                                                       Died of intracranial hemorrhage                      1.7                    5            4.3
  5         32/M           Lymphoma                 Dex 10mg/d×3d                                                                 Died of liver failure                                0.3                    10           13.3
  6         37/F           Sjögren\'s syndrome      The COP regimen(3 cycle)                                                      CR                                                   \>12                   5            0.7
  7         15/F           UCTD                     The COP regimen (4 cycle)                                                     CR                                                   \>45                   3            4.6
  8         21/F           EBV infection            HLH-2004 regimen (1 cycle)                                                    Died of acute hemorrhage of gastrointestinal tract   1.7                    7            6.6
  9         17/M           EBV infection            Methylprednisolone 40 mg/d×24d                                                CR                                                   \>22                   7            8.3
  10        46/M           EBV infection            Dex 15mg/d×4d                                                                 Died of septic shock                                 0.4                    6            10
  11        73/M           EBV infection            The COP regimen (7 cycle)                                                     Died of multi-organ failure                          6                      7            5.2
  12        26/F           CMV infection            IVIG/HLH-2004 regimen (1 cycle) →The CHOP regimen(2 cycle)                    CR                                                   \>24                   6            9
  13        24/F           CMV infection            The COP regimen (7 cycle)                                                     Died of respiratory failure                          2.2                    5            4.2
  14        69/F           MRSH infection           The COP regimen (2 cycle)                                                     Died of respiratory failure                          2.0                    6            5.2
  15        62/F           Fungal Infection         The COP regimen (7 cycle)                                                     stable                                               \>8                    4            5.8
  16        44/F           Malignant tumour?        Methylprednisolone 40 mg/d×5d                                                 Died of multi-organ failure                          0.4                    8            7.7
  17        56/M           Lymphoma?                The CHOP regimen (2 cycle) →Splenectomy→The Hyper-CVAD regimen (1cycle)       stable                                               \>13                   6            5.7
  18        18/M           indefinite               HLH-2004 regimen (1 cycle)                                                    Died of intracranial hemorrhage                      0.2                    3            4.2

HLH-2004, dexamethasone, etopside and Ciclosporin A; CHOP, cyclophosphamide, adviamycin, vincristine and prednisolone; COP, cyclophosphamide, vincristine and prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; DEX, dexamethasone; CR, complete response; UCTD, undifferentiated connective tissue disease; EBV, Epstein-Barr virus; CMV, cytomegalovirus; MRSH, methicillin-resistant Staphylococcus hominis.
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